CN102802442A - Prenatal milk-derived composition for preventing the risk of low birthweight of newborns - Google Patents
Prenatal milk-derived composition for preventing the risk of low birthweight of newborns Download PDFInfo
- Publication number
- CN102802442A CN102802442A CN2010800266005A CN201080026600A CN102802442A CN 102802442 A CN102802442 A CN 102802442A CN 2010800266005 A CN2010800266005 A CN 2010800266005A CN 201080026600 A CN201080026600 A CN 201080026600A CN 102802442 A CN102802442 A CN 102802442A
- Authority
- CN
- China
- Prior art keywords
- milk
- cow
- birth weight
- risk
- pregnant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
Abstract
An object of the present invention is to develop a pharmaceutical composition or a food composition that ameliorates the low birthweight of newborns and prevents the birthweight from decreasing to a level below the average body weight (low body weight at birth) through improvement of nutrients during pregnancy. The present invention provides an agent for preventing low birthweight comprising milk phospholipids as an active ingredient, by which the low birthweight of newborns can be prevented.
Description
Technical field
The invention belongs to the health food technology field, more specifically, the invention belongs to the food compositions technical field that is used to prevent the risk that birth weight reduces.
Background technology
When being born in 1975, be less than or equal to 2500 gram birth weight reduction problems in Japan and improve, yet since nineteen eighty, the ratio that birth weight reduces in Japanese neonate is increasing always.Reason is following behind.Before 1980, the suggestion pregnant woman has enough nutrition to take at period of gestation, but from 1975-1980, even in the general citizen of Japan, and beginning is pointed out that the energy Excessive Intake also can cause fat or various metabolic problems.The pregnant woman is warned at the nutrient excess of period of gestation and takes in, and may cause abnormal labour or cause complications of pregnancy.In addition, also relate to the requirement of pregnant woman's cosmetics.Point out that also other reasons is the variation of obstetrics' medical science theory, the increase of premature's quantity, young woman's smoking rate increased in more than 20 year old, (non-patent literatures 1) such as influences that multifetation increases.
The connatae body weight of neonate reduce maybe with diabetes, hypertension, disease associations such as coronary artery disease (non-patent literature 2), in addition, also disclosing this also maybe be relevant with metabolic syndrome.In addition, the newborn respiration function of LBW is jejune mostly, in such baby, and the 25% generation premature labor apnea of can having an appointment.There is report to point out to exist the onset risk of brain or other organ diseases.
As stated, the connatae under-weight of neonate can produce various burdens, disorder or risk, so think and prevent that connatae under-weight from being important.As its countermeasure, thinking importantly has good eating habit (regularly having breakfast etc.) (non-patent literature 3).In addition, the connatae infant of low-birth weight's prediction and diagnostic method for example are in the news in patent documentation 1.
Need to prove, the gestational period nutrient such as vitamin necessity, the particularly gestational period in the absorption of folic acid be suggested more than 40 year.Think that always folic acid deficiency forms relevant with the inhibition central nervous system.Beginning folic acid is taken in before conceived, and this is because it can reduce the risk (NTD) (non-patent literature 4) of NTD.In addition, pregnant woman's cobalamin or the correlation (non-patent literature 5) between folic acid deficiency and the connatae body weight reduction of neonate are also disclosed.
Patent documentation 1: the special table of Japan 2002-512047 number
Non-patent literature 1:http: //www.aiiku.or.jp/aiiku/jigyo/contents/kaisetsu/ks0207/ks0 207.htm
Non-patent literature 2:Lancet 1999, the 353 volumes, the 9166th phase, 1789-1792 page or leaf
Non-patent literature 3:http: //www.asagumi.jp/asagohan/txt/1-6
Non-patent literature 4:Report Concerning Reduction in the Risk of the Onset of Neural Tube Defects (December 2000) Conference concerning Risk of the Onset of Inborn Error (about the report (putting down in December, 12) that reduces the NTD onset risk about reducing the seminar of birth defect occurrence risk)
Non-patent literature 5:Asia Pac Journal of Clinical Nutrition 2006, the 15 volumes, the 538-543 page or leaf
Summary of the invention
The 1st problem of the application's invention is to develop a kind of pharmaceutical composition or food compositions; Said pharmaceutical composition or food compositions are through improving pregnancy period nutrition; Improve neonatal birth weight and reduce, prevent that neonatal weight from dropping to and be lower than neonatal weight average level (below be also referred to as neonatal birth weight reduce).
In addition; The 2nd problem of the present invention is to invent a kind of pharmaceutical composition or food compositions that is used to prevent neonatal birth weight reduction; Said pharmaceutical composition or food compositions are towards following pregnant woman: owing to causing nutrition unbalanced with fast food as staple food and hypovitaminosis, and then the risk that possibly cause birth weight to reduce increases (under the background condition that LBW neonate quantity increases in the recent period).
All the time, folic acid uses as period of gestation pregnant woman's prescription nutrient, and folic acid is a kind of water soluble vitamin, and known to instabilities such as light, acid, alkali, heat.The beverage (for example milk etc.) that contains folic acid etc. is pointed out in long term storage, to observe degradation problem under the folic acid concentration, for example (Nihon Chikusan Gakkaiho (Japanese animal science can be reported) 2009, the 80 volumes, 41-45 page or leaf).Therefore, be desirable to provide a kind of gravidic nutrient that is different from folic acid, safety, certain and medicine that has good keeping qualities or special purposes food or the dietary supplement that is used for gestation always.
Cow's milk phosphatide (cow's milk phosphatide or from the phosphatide of cow's milk) is safe food composition, and is thermally-stabilised excellent with keeping quality.Through taking in cow's milk phosphatide, successfully prevented the birth weight reduction, pregnant woman and neonatal health have been made very big contribution.
The application inventors etc. give and cow's milk phosphatide through the rat of B that the pregnancy period is deficient in vitamin, estimate the influence of vitamin(e) B group to pregnant mouse, and through just postnatal young mouse body weight, body length and organ weight estimate the influence of vitamin(e) B group to tire mouse phase tire mouse.As a result, the application inventor finds: for the pregnant mouse (conceived female mouse) of the category-B that is deficient in vitamin, children mouse body weight reduces during birth, yet, give and cow's milk phosphatide through pregnant mouse (conceived female mouse) the category-B that is deficient in vitamin, children mouse body weight reduces in the time of can preventing to be born.Thereby accomplished the application's invention.
This specification comprises partly or entirely the content of putting down in writing as in Japanese patent application 2009-143615 number specification of the application's basis for priority and/or the accompanying drawing.
The application invents the following extremely excellent effect of performance: through using the composition (cow's milk phosphatide) as the safety of food picked-up, can prevent that birth weight from reducing.And then in general, liposoluble vitamin is difficult to decompose than water soluble vitamin.Therefore, fat-soluble cow's milk phosphatide is excellent aspect long-term retentivity (not decomposing).
Description of drawings
[Fig. 1] is illustrated in gestation and opened the result that abdomen takes out the tire mouse and measures tire mouse quantity and body weight thereof on the 20th day.
The specific embodiment
The application's invention comprises a kind of birth weight depressant that prevents, the said birth weight depressant that prevents contains cow's milk phosphatide as active ingredient, can prevent that through the said birth weight depressant that prevents birth weight from reducing.The application's invention comprises that a kind of minimizing birth weight reduces the risk agent, and said minimizing birth weight reduces the risk agent and contains cow's milk phosphatide as active ingredient, reduces the risk agent through said minimizing birth weight and can reduce the risk that birth weight reduces.And then; The application's invention also comprises a kind of birth weight depressant that prevents; The said birth weight depressant that prevents contains cow's milk phosphatide as active ingredient, prevents that through said the birth weight depressant from can prevent to reduce because of pregnant woman's birth weight that category-B causes that is deficient in vitamin.The application's invention comprises that a kind of minimizing birth weight reduces the risk agent; Said minimizing birth weight reduces the risk agent and contains cow's milk phosphatide as active ingredient, reduces the risk agent through said minimizing birth weight and can reduce the risk that birth weight that category-B causes reduces that is deficient in vitamin because of the pregnant woman.
In addition; The application's invention comprises a kind of pregnant drug thing; Through being that the pregnant woman gives and said pregnant drug thing to mother neonate, can reducing and suffer from the risk that reduces relevant diabetes, hypertension or coronary artery disease with birth weight after this neonate grows up.
1. prevent that birth weight from reducing
The food (category-B is deficient in vitamin) that absorbs the category-B that is deficient in vitamin at period of gestation very likely causes the birth weight of this woman to reduce.Beat allly be that discoveries such as the application inventor are deficient in vitamin the pregnant woman of food of category-B when giving with cow's milk phosphatide to picked-up, can suppress significantly or prevent that birth weight from reducing.
Being used to of the application invention prevents that the composition that birth weight reduces from containing cow's milk phosphatide as active ingredient, and comprises:
(1) prevents the birth weight depressant, can prevent that birth weight from reducing;
(2) reduce birth weight and reduce the risk agent, can reduce the risk that birth weight reduces;
(3) prevent the birth weight depressant, can prevent to reduce because of pregnant woman's birth weight that category-B causes that is deficient in vitamin; And
(4) reduce birth weight and reduce the risk agent, can reduce the risk that birth weight that category-B causes reduces that is deficient in vitamin because of the pregnant woman;
1-1. be used to prevent the composition of birth weight reduction
In the application's invention,, can enumerate cow's milk phosphatide as the active ingredient of the composition that is used to prevent that birth weight from reducing.As cow's milk phosphatide, can enumerate with ethanol etc. and from milk, extract lipid components, carry out the extraction of cow's milk phosphatide then with acetone.
For example can prepare according to disclosed known method in TOHKEMY 2002-226394A number from the phosphatide of cow's milk.Specifically, from the phosphatide of cow's milk can according to known method [" Lipid Chemistry (lipid chemistry) (Biochemistry Experiment lecture 3) ", Japanese biochemistry association compiles, the 23rd page, the same people of Tokyo chemistry, 1974; " lipid II phospholipid (lipid II phosphatide) (neoformation chemical experiment lecture 4) "; Japan biochemistry association compiles; The 7th page; Carry out solvent extraction whey that side reaction produces when the cheese that the same people of Tokyo chemistry, 1991], side reaction produces when cream prepares, cheese preparation or the skim milk or prepare through utilizing various chromatographic processes that this extract is carried out fractionation.For example, also can be from the phosphatide of cow's milk from cream, butter or the accessory substance butter serum (butter serum) when producing cream as the composition acquisition that is insoluble to acetone (solvent).Butter serum also is applied to the milk market segment, therefore can buy (for example Zelanian Tatua corporate system).Contain the MFGM that a large amount of parts has phosphatide in the butter serum, so butter serum is suitable as the raw material that extracts phosphatide.
For separating phospholipids from butter serum, utilize phosphatide to be insoluble to the character of acetone.Through acetone extraction repeatedly, remove the acetone soluble composition that contains neutral lipid, obtain to contain acetone insoluble composition through concentrated phosphatide.Above-mentioned acetone insoluble composition through the concentrated acetone of removing of vacuum, is carried out freeze drying with this concentrate through after sterilization.Dry thing is pulverized, obtained phospholipid composition from cow's milk.For example can enumerate as stated the phosphatide that contains 85% (weight %) that consists of of the phospholipid composition that obtains.In phospholipid composition, there is the composition that contains choline such as phosphatid ylcholine and sphingomyelins.
And then, as cow's milk phosphatide, also can use " cow's milk phosphatide concentrate " (to comprise about 5 weight % choline; 85 weight % lipids, 10 weight % ash contents, 4 weight % carbohydrate, and 1 weight % moisture) or contain the dairy products " Hohoemi " (Mingzhi Dairy Co., Ltd's system) of cow's milk phosphatide.
2. pregnant drug thing
The medicine of the application's invention is following pregnant drug thing, that is,
(1) pregnant drug thing (preventing the birth weight depressant) prevents that birth weight from reducing;
(2) pregnant drug thing (reduce birth weight and reduce the risk agent) reduces birth weight and reduces risk; Perhaps
(3) pregnant drug thing through being that the pregnant woman gives and this pregnant drug thing to mother neonate, can reducing and suffer from the risk that reduces diseases associated with birth weight after this neonate grows up.
As the medicine of the application invention, can enumerate with cow's milk phosphatide as active ingredient,
(1) pregnant drug thing (preventing the birth weight depressant) prevents that birth weight from reducing;
(2) pregnant drug thing (reduce birth weight and reduce the risk agent) reduces birth weight and reduces risk;
(3) pregnant drug thing through being that the pregnant woman gives and this pregnant drug thing to mother neonate, can reducing and suffer from the risk that reduces diseases associated with birth weight after this neonate grows up.
The medicine of the application's invention can adopt suitable formulations such as powder, granule, tablet, capsule and solution.When preparation, can add auxiliary agent commonly used in the preparations such as excipient, adhesive, disintegrant, lubricant.As excipient, for example comprise starch, lactose, sucrose, methylcellulose, carboxymethyl cellulose, sodium alginate, calcium monohydrogen phosphate, synthetic aluminium silicate, microcrystalline cellulose, polyvinylpyrrolidone (PVP), hydroxypropul starch (HPS) etc.In addition, as adhesive, for example comprise the aqueous solution or their water or the ethanolic solution etc. of starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), Arabic gum powder, gelatin, glucose, sucrose etc.As disintegrant, for example comprise starch, carboxymethyl cellulose, calcium carboxymethylcellulose, microcrystalline cellulose, hydroxypropul starch, calcium phosphate etc.And then; As lubricant, for example comprise Brazil wax, light anhydrous silicic acid, synthetic aluminium silicate, natural aluminium silicate, synthetic magnesium silicate, hydrogenated oil and fat, hydrogenated vegetable oil derivative (Sterotex HM), sesame oil, cera alba, titanium oxide, Aluminium Hydroxide gel stearic acid, calcium stearate, dolomol, talcum, calcium monohydrogen phosphate and lauryl sodium sulfate etc.
The administering mode of the medicine of 2-1 the application invention
For the medicine of the application's invention, particularly,
(1) pregnant drug thing prevents that birth weight from reducing;
(2) pregnant drug thing reduces birth weight and reduces risk; Perhaps
(3) pregnant drug thing through being that the pregnant woman gives and this pregnant drug thing to mother neonate, can reducing and suffer from the risk that reduces diseases associated with birth weight after this neonate grows up,
Can oral or non-enteron aisle give with, but preferred oral give with.
In addition, about the oral dose of the medicine of the application invention, for example, in choline, 60mg～3.5g/ days, preferred 100mg～3.5g/ days, more preferably 200mg～3.5g/ days, more preferably in 350mg～3.5g/ days the scope.For " cow's milk phosphatide the concentrate " (choline that contains about 5 weight %.85 weight % lipids; 10 weight % ash contents, 4 weight % carbohydrate, and 1 weight % moisture) dosage; 1.4g～75g/ days, preferred 2.4g～75g/ days, more preferably 4.8g～75g/ days, more preferably be desirable (American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) in 7.5g～75g/ days the scope; 2005, the 82 volumes, the 111-117 page or leaf; American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine), 2006, the 83 volumes, 905-911 page or leaf; European Journal of Nutrition (European nutrition magazine), 2007, the 46 volumes, 300-306 page or leaf, Dietary Reference Intakes (dietary reference absorption), the 411st page).
In the application's invention, it is comparatively desirable before pregnancy, promptly to begin to take in the pregnant drug thing that prevents the birth weight reduction.The preferred whole pregnancy period is absorbed once this pregnant drug thing at least, preferably continues picked-up this pregnant drug thing (for example every day) in the whole pregnancy period.
2-2. the medicine of the application's invention is given and object
The medicine of the application's invention can be given and all pregnant woman, and said medicine is specially (1) pregnant drug thing (preventing the birth weight depressant), prevents that birth weight from reducing; (2) pregnant drug thing (reduce birth weight and reduce the risk agent) reduces birth weight and reduces risk; Or (3) pregnant drug thing, through being that the pregnant woman gives and this pregnant drug thing to mother neonate, can reducing and suffer from the risk that reduces diseases associated with birth weight after this neonate grows up.The medicine of the application's invention is particularly suitable for nutrition and takes in unbalanced maternity dress usefulness.Said pregnant woman's object lesson comprises avitaminous pregnant woman, and example comprises the pregnant woman of vegetarian and Vitamin B deficiency more specifically.Vitamin B deficiency is meant folic acid deficiency, Vitamin B2 deficiency, Vitamin B6 deficiency and vitamin B12 deficiency here.
3. the pregnant woman is with special purposes food or dietary supplement
Pregnant woman of the present invention uses special purposes food or dietary supplement to be: (1) pregnant woman uses dietary supplement with special used food or pregnant woman, prevents that birth weight from reducing; (2) pregnant woman uses dietary supplement with special used food or pregnant woman, reduces birth weight and reduces risk; Perhaps (3) pregnant woman uses dietary supplement with special used food or pregnant woman; Through mother neonate is that the pregnant woman absorbs this pregnant woman and uses dietary supplement with food or pregnant woman, can reduce and suffer from the risk that reduces diseases associated with birth weight after this neonate grows up.
The special purposes food or the dietary supplement of the application's invention contain cow's milk phosphatide as active ingredient, and can be solid, shaped (for example powder and granule), pasty state, any in liquid state or the suspendible shape.For example when being mixed with beverage, additive commonly used in the time of also can adding sweetener, acidulant, vitamin and other synthetic beverage agent.
The supplement (supplement) that the special used food of the application's invention or dietary supplement can be processed appropriate dosage forms such as powder, granule, tablet, capsule or solution.
And then the special used food of the application's invention or dietary supplement can be processed and contain the food additives of phosphatide as active ingredient, are used to prepare the pregnant woman with special used food or dietary supplement.
For the special used food of the application invention or the intake of dietary supplement, for example, in choline, 60mg～3.5g/ days, preferred 100mg～3.5g/ days, more preferably 200mg～3.5g/ days, more preferably in 350mg～3.5g/ days the scope.For " cow's milk phosphatide the concentrate " (choline that contains about 5 weight %.85 weight % lipids; 10 weight % ash contents; 4 weight % carbohydrate, and 1 weight % moisture) intake, 1.4g～75g/ days, preferred 2.4g～75g/ days, more preferably 4.8g～75g/ days, more preferably be desirable (American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) 2005 in 7.5g～75g/ days the scope; The 82nd volume, the 111-117 page or leaf; American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) 2006, the 83 volumes, the 905-911 page or leaf; European Journal of Nutrition (European nutrition magazine), 2007, the 46 volumes, the 300-306 page or leaf, dietary reference is taken in, the 411st page).
Embodiment
{ the embodiment 1} pregnancy period is taken in the influence of cow's milk phosphatide
Experimental technique
In this experiment, rat is divided into four groups, every group of eight rats are divided 4 raisings.The rat body weight scope is 155g～165g when the experiment beginning, and (gestational period) rat body weight scope is 240g～290g when accomplishing experiment.At this moment, every group of body weight do not have notable difference.
(1) make 9 age in week female Wistar rats freely absorb low vitagen (hanging down vitagen: from AIN93G vitamin compound, remove vitamin B2, folic acid, cobalamin, reach lipotropin) or control Food (control group: AIN93G) 1 week.(table 1)
(2) make 10 week female Wistar rats mating in age.
(3) same day that will confirm mating (plug) was as gestation 0 day.Every group is freely absorbed test food (AIN93G, low vitagen, low vitagen+cow's milk phosphatide (2.6 weight %; Content of choline is approximately 40mg/g), low vitagen+lipotropin (0.25 weight %)).Freely absorb test food until pregnant 20 days.Need to prove that in low vitagen+cow's milk phosphatide, low vitagen+lipotropin and AIN93G, choline concentration is 0.1 weight %.
In the time of the 20th day,, open abdomen in gestation, take out the body weight that the tire mouse is measured the tire mouse then through the about 0.3mL of venous blood collection.Need to prove, will be defined as with the tire mouse number of abdomen usually 12+/-3 (eliminating exceeds the rat of this number) organize between the contrast.When statistical analysis, use Statview (SAS corporate system) one-way analysis of variance to carry out (Post-hoc:Scheffe) check of multiple ratio.
[table 1]
*So-called " the edible mixed vitamin of low vitamin " is meant through from the AIN93G mixed vitamin, removing the mixed vitamin that vitamin B2, cobalamin, folic acid prepare.
Experimental result
Because the low vitagen of picked-up is so tire mouse body weight reduces (Fig. 1).Yet because picked-up has added the low vitagen of cow's milk phosphatide, so tire mouse body weight improves, body weight has the tendency (Fig. 1 and table 2) of increase.
[table 2]
| Tire mouse body weight [g] | Standard deviation [g] | |
| Control group (n=68) | 3.156 | 0.288 |
| Low vitagen group (n=67) | 3.000 | 0.258 |
| Low vitagen+lipotropin group (n=70) | 3.068 | 0.217 |
| Low vitagen+cow's milk phosphatide group (n=34) | 3.199 | 0.249 |
This experiment shows that picked-up vitamin is essential to development of fetus.Show that further picked-up cow's milk phosphatide can improve because the fetal hypoplasia that is deficient in vitamin and causes.
Utilizability on the industry
The pregnant drug thing of the application's invention, special used food or dietary supplement performance can prevent the effect of the excellence that birth weight reduces.Therefore, said pregnant drug thing, special used food or dietary supplement can be used for medicine or food manufacturing industry.
All publications, patent and the patent application of here quoting all is introduced into this specification as reference.
Claims (10)
1. medicine is to contain from the phosphatide of the cow's milk pregnant drug thing as active ingredient, and said medicine prevents that the neonatal birth weight of said woman from reducing.
2. medicine is to contain from the phosphatide of the cow's milk pregnant drug thing as active ingredient, and said medicine prevents the risk that the neonatal birth weight of said woman reduces.
3. according to claim 1 or claim 2 medicine is the inadequate pregnant drug thing of the picked-up of Cobastab and folic acid.
4. like each described medicine in the claim 1 to 3, wherein, contain sphingomyelins and/or phosphatid ylcholine from the phosphatide of cow's milk.
5. like each described medicine in the claim 1 to 4, wherein, the content of choline is at least 60mg/day.
6. a pregnant woman is with special purposes food or dietary supplement, contains phosphatide from cow's milk as active ingredient, and said pregnant woman prevents the risk that the neonatal birth weight of said woman reduces with special purposes food or dietary supplement.
7. pregnant woman as claimed in claim 6 is with special purposes food or dietary supplement, for the inadequate pregnant woman of the picked-up of Cobastab and folic acid with special purposes food or dietary supplement.
Like claim 6 or 7 described pregnant woman with special purposes food or dietary supplement, wherein, contain sphingomyelins and/or phosphatid ylcholine from the phosphatide of cow's milk.
Like each described pregnant woman in the claim 6 to 8 with special purposes food or dietary supplement, wherein, the content of choline is at least 60mg/day.
10. one kind is used to modulate the food additives of pregnant woman with special purposes food or dietary supplement, contains phosphatide from cow's milk as active ingredient, prevents the risk that neonatal birth weight reduces.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009-143615 | 2009-06-16 | ||
| JP2009143615 | 2009-06-16 | ||
| PCT/JP2010/003959 WO2010146831A1 (en) | 2009-06-16 | 2010-06-15 | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102802442A true CN102802442A (en) | 2012-11-28 |
| CN102802442B CN102802442B (en) | 2014-05-07 |
Family
ID=42953864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080026600.5A Active CN102802442B (en) | 2009-06-16 | 2010-06-15 | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns |
Country Status (5)
| Country | Link |
|---|---|
| JP (2) | JP6043064B2 (en) |
| CN (1) | CN102802442B (en) |
| HK (1) | HK1175665A1 (en) |
| TW (1) | TWI528904B (en) |
| WO (1) | WO2010146831A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108057134A (en) * | 2017-12-26 | 2018-05-22 | 湖北回盛生物科技有限公司 | A kind of milk cow midwifery lubricant and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3060202A1 (en) * | 2013-10-21 | 2016-08-31 | Enzymotec Ltd. | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081934A1 (en) * | 2006-12-28 | 2008-07-10 | Meiji Dairies Corporation | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139131A0 (en) | 1998-04-21 | 2001-11-25 | Interleukin Genetics Inc | Fetal testing for prediction of low birth weight |
| JP3195594B2 (en) * | 1999-11-02 | 2001-08-06 | 明治乳業株式会社 | A food composition containing a milk-derived phospholipid. |
| JP2002226394A (en) | 2001-02-01 | 2002-08-14 | Meiji Milk Prod Co Ltd | Lipid metabolism improving composition |
| JP5300186B2 (en) * | 2006-08-23 | 2013-09-25 | 株式会社明治 | Milk-derived composition for pregnant women that suppresses increase in homocysteine concentration in blood |
| JP2009143615A (en) | 2007-12-17 | 2009-07-02 | Oji Paper Co Ltd | Packaging vessel for powder detergent |
-
2010
- 2010-06-15 JP JP2011548707A patent/JP6043064B2/en active Active
- 2010-06-15 WO PCT/JP2010/003959 patent/WO2010146831A1/en active Application Filing
- 2010-06-15 TW TW099119530A patent/TWI528904B/en active
- 2010-06-15 CN CN201080026600.5A patent/CN102802442B/en active Active
-
2013
- 2013-03-11 HK HK13103020.3A patent/HK1175665A1/en unknown
-
2016
- 2016-07-19 JP JP2016141636A patent/JP6147900B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081934A1 (en) * | 2006-12-28 | 2008-07-10 | Meiji Dairies Corporation | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Non-Patent Citations (1)
| Title |
|---|
| YESIM OZARDA ILCOL ET AL: "Choline status in newborns，infants，children，breast-feeding women，breast-fed infants and human breast milk", 《JOURNAL OF NUTRITIONAL BIOCHEMISTRY》, vol. 16, 31 December 2005 (2005-12-31) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108057134A (en) * | 2017-12-26 | 2018-05-22 | 湖北回盛生物科技有限公司 | A kind of milk cow midwifery lubricant and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201103443A (en) | 2011-02-01 |
| JP2012530046A (en) | 2012-11-29 |
| JP2016185985A (en) | 2016-10-27 |
| TWI528904B (en) | 2016-04-11 |
| JP6147900B2 (en) | 2017-06-14 |
| CN102802442B (en) | 2014-05-07 |
| JP6043064B2 (en) | 2016-12-14 |
| WO2010146831A1 (en) | 2010-12-23 |
| HK1175665A1 (en) | 2013-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2375079C2 (en) | Polyvitaminic and mineral food additives | |
| CN106983136A (en) | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof | |
| CN105581302B (en) | Jelly for providing energy required by parturient childbirth and preparation method thereof | |
| JP6483024B2 (en) | Composition | |
| WO2018077276A1 (en) | Immunity-enhancing composition and preparation method therefor | |
| WO2015105981A2 (en) | Conditional essentiality of hmb | |
| US20230027781A1 (en) | Prenatal Dosage Forms, Methods of Administration and Kits Thereof | |
| CN102802442B (en) | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns | |
| JP5158307B2 (en) | Fat loss promoter and metabolic disorder syndrome improver | |
| WO2005094854A1 (en) | Modified nutraceutical composition | |
| TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
| JP5819041B2 (en) | Composition for improving nutritional status of elderly, reducing the number of fever and / or improving immunity | |
| US20180228819A1 (en) | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation | |
| PT2908828T (en) | Galactagogue compositions based on phosphatidylserine | |
| CN107921010A (en) | The prevention of hypertension and angiocardiopathy | |
| JP2001269135A (en) | Nutritional composition capable of promoting body protein accumulation efficiency | |
| JP5300186B2 (en) | Milk-derived composition for pregnant women that suppresses increase in homocysteine concentration in blood | |
| AU2011101216A4 (en) | Chocolate bars | |
| Hamed et al. | Overview of the Updates in Nutrient Profiles, Types, Indications and Side Effects of Infant Formula | |
| JP7134703B2 (en) | Adrenal hypofunction inhibitor | |
| WO2024223906A1 (en) | Composition for use in a subject | |
| RU2616399C1 (en) | Method for producing biologically active product for adaptive feeding and biologically active product for adaptive feeding | |
| JP5870181B1 (en) | Serum cholesterol level and / or blood lipid level improver | |
| EP4444111A1 (en) | Prenatal supplement compositions for increasing breastmilk micronutrient levels | |
| Suprabha | Role of Madhuraushadha Siddha Avaleha as Garbhini Rasayana in the 6th and 7th Month of Pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1175665 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1175665 Country of ref document: HK |